Analysed Chugai Pharmaceutical Co Ltd (CHGCF:OTCMKTS) News Sources
Chugai Pharma introduces “Elevidys” as Japan’s first regenerative medical product for Duchenne muscular dystrophy
Pharmabiz
Zenyaku Kogyo obtains Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat autoimmune haemolytic anaemia
Pharmabiz
Ten63 Therapeutics Closes Strategic Financing, Bringing Total Funding to More Than $45M to Scale the Next-Generation of Artificial Intelligent Drug Discovery
Le Lézard
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
MarketWatch
Protara Therapeutics: TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
FinanzNachrichten.de
F. Hoffmann-La Roche Ltd: FDA accepts New Drug Application for Roche's giredestrant in ESR1-mutated, ER-positive advanced breast cancer
FinanzNachrichten.de
Making complex and innovative products at scale, the next frontier, say pharma chiefs
The Hindu BusinessLine
What is the current price of Chugai Pharmaceutical Co Ltd (CHGCF:OTCMKTS)?
The current price of Chugai Pharmaceutical Co Ltd (CHGCF:OTCMKTS) is $67.9475.
Chugai Pharmaceutical Co Ltd (CHGCF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of Chugai Pharmaceutical Co Ltd (CHGCF:OTCMKTS) since the previous trading day is $3.95.
Chugai Pharmaceutical Co Ltd (CHGCF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of Chugai Pharmaceutical Co Ltd (CHGCF:OTCMKTS) since the previous trading day is 6.17%.
What is This Week's average sentiment score for Chugai Pharmaceutical Co Ltd (CHGCF:OTCMKTS)?
This Week's average sentiment score for Chugai Pharmaceutical Co Ltd (CHGCF:OTCMKTS) is 66 out of 100.
What is This Week's average sentiment for Chugai Pharmaceutical Co Ltd (CHGCF:OTCMKTS)?
This Week's sentiment for Chugai Pharmaceutical Co Ltd (CHGCF:OTCMKTS) is .
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.